T Cell Immunotherapy for Advanced Cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of cancer (blood or solid tumor) that has not responded to standard treatment
- You are between 18 and 75 years old with an expected survival of at least 3 months
- Your blood counts, liver, kidney, heart, and lung function are adequate based on recent lab tests and imaging
- You are in good overall health with minimal symptoms (ECOG score 0–1, meaning you can carry out daily activities)
- You have not received immunosuppressant medications in the past month and have no active infections requiring treatment
- You do not have certain viral infections (Hepatitis B or C, HIV) or serious heart conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune-cell treatment made from your own blood to target certain solid tumors. You may be eligible if your tumor has a specific protein pattern and you have tried standard treatments without success.
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
This trial tests a personalized treatment that uses your own immune cells, modified to recognize and attack your cancer. It may help people with advanced solid tumors who have not improved with standard treatments.
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
This trial is testing a new CAR-T cell therapy given as an injection for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. CAR-T therapy uses your own immune cells to target and attack cancer cells. It may be an option if you have tried other treatments and they are no longer working.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.